GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
19 Juli 2023 - 1:05PM
GeneDx, a leader in delivering improved health outcomes through
genomic and clinical insights, and Prognos Health, the largest
real-world integrated data marketplace, today announced a strategic
partnership to shorten the treatment odyssey for rare disease
patients via real world data. The partnership offers life science
companies a comprehensive de-identified dataset specific to rare
disease to accelerate access to life saving therapies.
Through this partnership, the Prognos Marketplace will integrate
GeneDx’s de-identified rare disease data, including regularly
updated data as GeneDx continues to add new genomic and health
information retrieved through its whole genome and whole exome
sequencing tests. Biopharma companies who work with Prognos will
then be automatically alerted about clinicians who have newly
diagnosed patients and may benefit from therapies that have been
approved by the U.S. Food and Drug Administration (FDA).
"Patients with rare diseases oftentimes have to endure a
diagnostic odyssey of approximately eight years, meaning that not
months, but years are wasted without an accurate diagnosis and
without knowledge of or access to an FDA-approved therapy,” said
Kareem Saad, Chief Transformation Officer of GeneDx. “GeneDx is
dedicated to ending the diagnostic odyssey for patients and their
families, and this partnership gives us the opportunity to go a
step further to connect clinicians and their patients with rare
diseases to appropriate treatment options and ultimately improve
health and health economic outcomes.”
GeneDx has a genetic database enriched for rare disease with
samples from more than 1.3 million patients, including more than
450,000 exomes and genomes. Prognos’ Marketplace includes lab and
health records on more than 325 million de-identified patients, as
well as claims data, pharmacy prescription data, among other data
types.
"Prognos Health's mission has always been to unlock the power of
data to improve health, and this partnership further enables us to
provide actionable insights in rare disease that can help
clinicians make more informed decisions and ensure patients receive
the right treatment at the right time," said Sundeep Bhan, Chief
Executive Officer of Prognos Health. "With the rare disease
genomics data and expertise available to us through partners like
GeneDx, our life science clients can leverage the Prognos
Marketplace to bring about a paradigm shift in the treatment of
rare diseases."
About GeneDxGeneDx (Nasdaq: WGS) delivers
personalized and actionable health insights to inform diagnosis,
direct treatment and improve drug discovery. The company is
uniquely positioned to accelerate the use of genomic and
large-scale clinical information to enable precision medicine as
the standard of care. GeneDx is at the forefront of transforming
healthcare through its industry-leading exome and genome testing
and interpretation, fueled by one of the world’s largest, rare
disease data sets. For more information, please visit
www.genedx.com and connect with us on LinkedIn, Facebook, Twitter
and Instagram.
About Prognos Health
Prognos Health is a real-world data (RWD) company that unlocks
the power of data to improve health. Prognos offers the leading
managed RWD marketplace, accelerating the development and delivery
of innovative therapies and improving health outcomes by offering
fully integrated and harmonized lab and health records on more than
325 million de-identified patients. Prognos Health's platform
provides a comprehensive and integrated view of patient health,
enabling researchers, payers, and providers to make better
decisions about care.
GeneDx Investor Relations Contact:Tricia
TruehartInvestors@GeneDx.com
GeneDx Media Contact:Maurissa MessierPress@GeneDx.com
Prognos Health Media Contact: Ashley
Triscuitatriscuit@prognoshealth.com
GeneDx (NASDAQ:WGS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
GeneDx (NASDAQ:WGS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024